0000925421-18-000294.txt : 20180820
0000925421-18-000294.hdr.sgml : 20180820
20180820171230
ACCESSION NUMBER: 0000925421-18-000294
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180816
FILED AS OF DATE: 20180820
DATE AS OF CHANGE: 20180820
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Novartis Bioventures Ltd
CENTRAL INDEX KEY: 0001297709
STATE OF INCORPORATION: D0
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38130
FILM NUMBER: 181028858
BUSINESS ADDRESS:
STREET 1: C/O NOVARTIS INTERNATIONAL AG
STREET 2: WSJ-200.220
CITY: CH-4002 BASEL
STATE: V8
ZIP: 0000000000
BUSINESS PHONE: 41-61-324-6210
MAIL ADDRESS:
STREET 1: C/O NOVARTIS INTERNATIONAL AG
STREET 2: WSJ-200.220
CITY: CH-4002 BASEL
STATE: V8
ZIP: 0000000000
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: NOVARTIS AG
CENTRAL INDEX KEY: 0001114448
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38130
FILM NUMBER: 181028859
BUSINESS ADDRESS:
STREET 1: LICHTSTRASSE 35
CITY: BASEL
STATE: V8
ZIP: CH 4056
BUSINESS PHONE: 01141613241111
MAIL ADDRESS:
STREET 1: LICHTSTRASSE 35
CITY: BASEL
STATE: V8
ZIP: CH 4056
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AILERON THERAPEUTICS INC
CENTRAL INDEX KEY: 0001420565
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 281 ALBANY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-995-0900
MAIL ADDRESS:
STREET 1: 281 ALBANY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2018-08-16
0001420565
AILERON THERAPEUTICS INC
ALRN
0001297709
Novartis Bioventures Ltd
C/O NOVARTIS INTERNATIONAL AG
WSJ-200.220
BASEL
V8
CH-4002
SWITZERLAND
0
0
1
0
0001114448
NOVARTIS AG
LICHTSTRASSE 35
BASEL
V8
CH 4056
SWITZERLAND
0
0
1
0
Common Stock
2018-08-16
4
S
0
8808
2.10
D
2425970
D
Common Stock
2018-08-17
4
S
0
8700
2.10
D
2417270
D
Reflects sales of common stock executed in multiple transactions at prices ranging from $2.02 to $2.20. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities.
Reflects sales of common stock executed in multiple transactions at prices ranging from $2.02 to $2.18. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
/s/ Bartosz Dzikowski, Secretary of the Board of Novartis Bioventures Ltd
2018-08-20
/s/ Florian Muellershausen, Authorized Signatory on behalf of Novartis Bioventures Ltd
2018-08-20
/s/ Bartosz Dzikowski, Authorized Signatory on behalf of Novartis AG
2018-08-20
/s/ Florian Muellershausen, Authorized Signatory on behalf of Novartis AG
2018-08-20